Friday, October 13, 2017 News Recap: Research & Discoveries After an intense hunt, researchers at the Norwegian University of Science and Technology (NTNU) can now describe an important part of the disease's guerrilla tactics: how hepatitis C converts innocent cells into outright virus factories. How hepatitis C hides in the body. Apparently, liver cancer can be caught at an early stage through a newly developed blood test, improving the odd...
Hepatocellular carcinoma (HCC) is the third cause of cancer-related death and accounts for more than 90% of primary liver cancers. It is most frequently diagnosed at an advanced stage in patients with chronic liver injury and cirrhosis. Despite dedicated research in the last few decades, significant advancements in the treatment of HCC have not been achieved, and HCC still belongs to the category of cancers with a very low 5-year survival rate of less t
George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC). The study aimed to understand the real-world effectiveness of antiviral agents sofosbuvir (SOF), ledipasvir/sofosbuvir (LDV/ SOF) and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) by h
Dr. Gonzalez and his team developed a model to determine if it was cost-effective to treat U.S. hepatitis C with all oral direct acting antivirals for HCC patients on the waiting list for liver transplant. The goal was to determine if was more cost-effective to treat pre-transplant or post-transplant. Data related to transition to progression of HCC and progression of disease and the efficacy of antiviral therapy were used for the analysis. The study foun